[Testosterone assays using non recommended methods lead to misdiagnosis in women].

Ann Biol Clin (Paris)

Unité d'hormonologie et immunoanalyse, Hôpital Saint-Antoine, Paris.

Published: December 2011

French and US endocrine societies recommend using GC-MS or RIA after purification (extraction + chromatography) to assess blood levels of testosterone in women. However, most of laboratories use automatized methods that have to be reserved to measure testosterone levels in men. The aim of this study was to show the consequences of analytical discrepancies of some immunological methods on the diagnostics values of testosterone levels assayed in women. Compared to GC-MS the correlations of the assayed levels varied (Spearman's rank correlation coefficients: 0.935; 0.793; 0.841; 0.852 respectively for RIA Immunotech™ with extraction and chromatographic purification; Testosterone Access-DxI800®; Testosterone Immulite 2000®; Testosterone II Cobas E601®). The testosterone levels allowed an accurate conclusion in 95.2 %; 75.8 %; 77.4 %; 89.8 % of patients, respectively. The agreement with GC-MS results was very good for RIA method (κ=0,840), moderate for DxI800® method (κ=0,414), moderate for Immulite® method (κ=0,467), good for Cobas® method (κ=0,667). Most of discordances are false hypertestosteronemia. The use of non recommended methods may leads to nosological errors (misclassification rates of 10 to 25% with automatized methods) that causes loss of chance in part of female patients.

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2010.0486DOI Listing

Publication Analysis

Top Keywords

testosterone levels
12
recommended methods
8
automatized methods
8
testosterone
7
methods
5
levels
5
[testosterone assays
4
assays recommended
4
methods lead
4
lead misdiagnosis
4

Similar Publications

Background: Radiotherapy is often given with androgen deprivation therapy for prostate cancer which causes a reduction in testosterone levels, which when below castrate levels, can cause the prostate specific antigen (PSA) levels to be artificially low.

Aim: To determine if high-level radiotherapy clinical trials are underestimating biochemical recurrence (BCR) rates due to inadequate measurement of testosterone levels.

Methods: The study plans for clinical trials performed by the Radiation Therapy Oncology Group (RTOG [now NRG]) on clinicaltrials.

View Article and Find Full Text PDF

Background: Reported effects of Hormone Replacement Therapy (HRT) on late-life neurodegenerative disease are inconsistent. Variability in the timing and formulation of HRT, plus whether an individual carries an Apolipoprotein (APOE) e4 genetic risk variant for Alzheimer's Disease (AD), likely contribute to conflicting results. Additionally, whilst many studies have focused exclusively on the effects of exogenous oestrogen, the inclusion of testosterone in HRT appears protective against AD pathology, specifically in APOE e4 carriers.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Evidence suggests that a history of reduced estrogen exposure associates with greater Alzheimer's disease (AD) risk. However, the association of sex hormone levels with AD biomarkers has not been studied. We examined plasma levels of sex hormones in males and females with autosomal dominant AD due to the E280A Presenilin-1 mutation and age-matched non-carriers, and their relationship to AD brain pathology.

View Article and Find Full Text PDF

Background: Older females, particularly susceptible to Alzheimer's disease (AD), may be affected by hormonal fluctuation during life. We aim to investigate the relationship between changes in brain volume and sex steroid hormones over time. We hypothesize that levels of sex hormones (17ß-estradiol, progesterone, and testosterone) relate to changes in brain volume, especially in the hippocampus (HPC) and cerebellum (CB).

View Article and Find Full Text PDF

LN18178 is a standardized, synergistic combination of fruit rind and seed extracts, which has been reported to increase serum testosterone levels in young and aging males. The present 84-day randomized, double-blind, placebo-controlled study assessed the efficacy of LN18178 on the sexual function of aging male volunteers (age: 40-70 years; serum total testosterone: ≥ 300 ng/dL). The subjects with mild to moderate erectile dysfunction [5-item version of the International Index of Erectile Function (IIEF-5) scores 17-25] and low sexual desire (score < 3 on items 11 and 12 of IIEF) participated in this investigation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!